Medical cannabis company Cann Global Limited (ASX:CGB) has been granted an export permit that will see the company sell its “hard pill” medical cannabis in Australia.
Cann Global is an international medical cannabis company with partners in Australia, the United States, Israel, Asia, Africa and Canada. The company’s Canadian partner, Canntab Therapeutics Limited (CDS: PILLCN), produces a range of “hard pill” medical cannabis, which Cann Global will be bringing to Australia. Canntab and Cann Global share the hard pill venture 50/50.
The Canntab range includes a number of products, six of which will be coming to Australian patients. This includes two THC-heavy medications, two CBD-heavy medications and two THC/CBD blends. These are taken orally and use a patented delivery system.
The Canntab range will be available as soon as this April, as Cann Global’s permit to export the drugs has been granted by Health Canada. The company already has an import permit for Australia.
The new range will only be available with a prescription to Australians on the Special Access Scheme B (SAS B). As of February 2020, there are over 60,000 people on SAS B.
The hard pill range will also be made available to patients participating in the Cannabinoid Medicine Observational Study (CMOS). CMOS is a nationwide study that is assessing the safety and effectiveness of medical cannabis when used to treat conditions like Post Traumatic Stress Disorder (PTSD), epilepsy, fibromyalgia, chronic pain, and other mental health and neurological conditions. It includes over 20,000 people.
According to Cann Global, the Canntab medications are a unique form of medical cannabis.
Canntab is a leading innovator in cannabinoid and terpene blends in hard pill form therapeutic applications. These patented hard pills are unique in their pharmaceutical grade delivery systems which also provides precise dosing.
Canntab’s hard pill medical cannabis will be one of nearly 200 medical cannabis products available in Australia.
